Globe on Blue Background with abstract mountains

Registration is now open for the IASLC 2021 World Conference on Lung Cancer

Early Registration is open through July 30, 2021.
Abstract submissions will be accepted through April 9, 2021.
Blue image with Lungs

Registration Open for the IASLC 2021 CT Screening Symposium: Forefront Advances in Lung Cancer Screening

Join the Worldwide Virtual Event May 7-8, 2021
Annual Report 2020

2020 Annual Report


Registration is now open for the IASLC 2021 World Conference on Lung Cancer
Registration Open for the IASLC 2021 CT Screening Symposium: Forefront Advances in Lung Cancer Screening
2020 Annual Report

Homepage

The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

In Focus

ILCN Molecular Challenges Forum: ALK Pioneers and Progress

ALK research and therapy has evolved substantially since the original PROFILE 1001 study, which first evaluated crizotinib for patients with ALK-rearranged NSCLC. Patient advocate and ALK-positive survivor of more than 15 years, Linnea Olsen, was the fourth person in the world to go on that trial. Now, after more than a decade of research and six-phase I trials, Linnea shares her experiences with newer therapies and thoughts on the importance of being NED (no evidence of disease) vs. NDY (“not dead yet”). Moderator Ross Camidge, MD, and panelist Jessica Lin, MD, who is Linnea’s oncologist, provide expert perspectives on the current and future standards of care for patients with ALK-rearranged NSCLC and on what it is like living with lung cancer for more than a decade.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

See More

Our Work

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.

Lung Ambition Alliance

The IASLC has formed an alliance with three other founding organizations to allow scientists, specialists, advocates, and patients to break the barriers limiting progress and double 5-year survival rates of lung cancer by 2025.

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
45
Years Experience
15K
Number of Research Awards Funded
13.357
JTO Impact Factor
8K+
Members

Upcoming Meetings & Webinars

IASLC Meeting
May 07 - May 08 2021
IASLC Meeting
Oct 29 - Oct 30 2021
JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option.